You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage
  1. Didier Leys,
  2. Charlotte Cordonnier
  1. Stroke Department, Université Lille Nord de France, Lille, France
  1. Correspondence to Professor Didier Leys, Université Lille Nord de France (Faculté de médecine Henri-Warembourg), EA 2691 59045 Lille, France; didier.leys{at}univ-lille2.fr

https://doi.org/10.1136/jnnp.2010.206417

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Brain microbleeds (BMBs) are markers of a bleeding-prone state and are associated with hypertensive small-vessel arteriopathies, and cerebral amyloid angiopathies (CAA).1 They are present in 5% of healthy adults, one-third of patients with ischaemic stroke, one-half of patients with first-ever intracerebral haemorrhage (ICH) and 80% of patients with recurrent ICH.2 In the paper by Gregoire et al (see page 679),3 BMBs were more frequent in antiplatelet users with ICH than in matched antiplatelet users without ICH and ICH patients not under antiplatelet agents. They were more numerous in antiplatelet users with ICH compared with controls, with an odds ratio of 1.33 per additional BMB (only adjusted with leucoaraiosis). This study has two limitations: the small sample size, and probably exclusion of the most severe cases, because of the high case death …

    View Full Text

    Footnotes

    • Linked articles 198994.

    • Funding University of Lille.

    • Competing interests DL has had consultancy roles for and has contributed to advisory boards, steering committees, and adjudication committees for Sanofi–Aventis, Servier, Boehringer Ingelheim, AstraZeneca and Novo Nordisk, fees for which were paid towards research at ADRINORD (Association pour le Développement de la Recherche et de l'Innovation dans le Nord-Pas de Calais) or the research account of the hospital (délégation à la recherche du CHU de Lille). He was reimbursed for travel or accommodation expenses needed for the participation on these boards and committees. CC has participated in the BOREALIS trial (Sanofi–Aventis), fees for which were paid towards research at ADRINORD (Association pour le Développement de la Recherche et de l'Innovation dans le Nord-Pas de Calais). She was reimbursed for travel or accommodation and expenses needed for investigator meetings.

    • Provenance and peer review Commissioned; not externally peer reviewed.

    Linked Articles